…
M3, Inc. provides medical-related services primarily to physicians and other healthcare professionals through Internet. The company operates through five reporting segments: Medical Platform, Evidence Solutions, Career Solutions, Site Solutions, and Overseas. It operates m3.com, a members-only web site for providing information to the healthcare professionals; MR-kun, where member doctors can independently and continuously receive information on the m3com platform; QOL-kun that provides life support information other than medical information to members; AskDoctors, where registered doctors answer questions about health and illness from the general public; MDLinx for medical professionals in the United States; and Doctors.net.uk, a website that provides developing services for pharmaceutical companies, as well as provides drug information database in France, Germany, and Spain. The company also provides career services for doctors and pharmacists, recruitment, and posting job advertisements through m3.com CAREER. In addition, it engages in the sales activities and marketing operations for pharmaceuticals and medical devices; development, sale, and support business of electronic medical records and medical equipment for medical institutions; survey service for medical professionals; sale and marketing support businesses for pharmaceutical companies, etc. through the Internet; provision of management support and consulting services to medical institutions, and home-visit nursing services; and provision of human resources services for healthcare professionals, as well as operates clinical trial facilities. The company was formerly known as So-netM3, Inc. and changed its name to M3, Inc. in January 2010. M3, Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
M3 Inc is listed on the OTC Pink under ticker MTHRY; however, there is limited publicly available information and no clear, verifiable description of its core business. Because operational details and financial disclosures are scarce, long-term growth drivers are not identifiable from public sources and investors cannot reliably assess the company's attractiveness.
Primary risks include limited disclosure and transparency, low trading liquidity typical of Pink-listed securities, the potential for high volatility or fraud, and elevated regulatory and information risk that could impede valuation and exit opportunities.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Income before tax | 74318.00M | 96187.00M | 58264.00M | 34610.00M | 30942.00M |
| Minority interest | -2955.00M | -2263.00M | 7447.00M | 5490.00M | 3543.00M |
| Net income | 49028.00M | 63845.00M | 37822.00M | 21635.00M | 19577.00M |
| Selling general administrative | 64832.00M | 56067.00M | 45038.00M | 38699.00M | 36054.00M |
| Gross profit | 135186.00M | 123268.00M | 103400.00M | 72886.00M | 63843.00M |
| Reconciled depreciation | 7434.00M | 6274.00M | 5736.00M | 4493.00M | 1391.00M |
| Ebit | 70415.00M | 67364.00M | 58838.00M | 34452.00M | 27799.00M |
| Ebitda | 81821.00M | 102513.00M | 64111.00M | 39142.00M | 32345.00M |
| Operating income | 70511.00M | 66222.00M | 58000.00M | 34446.00M | 30698.00M |
| Other operating expenses | 61.00M | 163.00M | 476.00M | 264.00M | 10.00M |
| Interest expense | 69.00M | 52.00M | 111.00M | 39.00M | 12.00M |
| Tax provision | 22336.00M | 30078.00M | 17066.00M | 10457.00M | 9595.00M |
| Interest income | 2404.00M | 1097.00M | 404.00M | 312.00M | 154.00M |
| Net interest income | 2335.00M | 1045.00M | 293.00M | 273.00M | 142.00M |
| Income tax expense | 22336.00M | 30078.00M | 17066.00M | 10457.00M | 9595.00M |
| Total revenue | 230818.00M | 208159.00M | 169198.00M | 130973.00M | 113059.00M |
| Total operating expenses | 160307.00M | 141937.00M | 111198.00M | 96526.00M | 82361.00M |
| Cost of revenue | 95632.00M | 84891.00M | 65798.00M | 58086.00M | 49216.00M |
| Net income from continuing ops | 51982.00M | 66109.00M | 41198.00M | 24153.00M | 21347.00M |
| Net income applicable to common shares | 49028.00M | 63845.00M | 37822.00M | 21635.00M | 19577.00M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Total assets | 400645.00M | 345981.00M | 273123.00M | 221839.00M | 137306.00M |
| Intangible assets | 40711.00M | 25081.00M | 23019.00M | 20187.00M | 12735.00M |
| Other current assets | 3783.00M | 4560.00M | 2851.00M | 3607.00M | 3574.00M |
| Total liab | 91127.00M | 82028.00M | 65863.00M | 50238.00M | 35030.00M |
| Total stockholder equity | 302630.00M | 257840.00M | 199813.00M | 166111.00M | 98733.00M |
| Other current liab | 21047.00M | 23063.00M | 23994.00M | 16437.00M | 11914.00M |
| Common stock | 29192.00M | 29129.00M | 29036.00M | 28925.00M | 3709.00M |
| Capital stock | 29192.00M | 29129.00M | 29036.00M | 28925.00M | 3709.00M |
| Retained earnings | 231214.00M | 192912.00M | 137151.00M | 105246.00M | 88033.00M |
| Other liab | 24434.00M | 19442.00M | 10135.00M | 8561.00M | 7031.00M |
| Good will | 71342.00M | 57821.00M | 52854.00M | 51173.00M | 44129.00M |
| Other assets | 2420.00M | 2138.00M | 3677.00M | 3289.00M | 1467.00M |
| Cash | 118319.00M | 104253.00M | 89144.00M | 47948.00M | 27538.00M |
| Total current liabilities | 59580.00M | 57216.00M | 50308.00M | 38144.00M | 27999.00M |
| Other stockholder equity | 17180.00M | 6131.00M | 1448.00M | -1079.00M | 653.00M |
| Property plant equipment | 19034.00M | 12540.00M | 12198.00M | 9774.00M | 1563.00M |
| Total current assets | 203471.00M | 198874.00M | 164109.00M | 121545.00M | 63986.00M |
| Net tangible assets | 190577.00M | 174938.00M | 123940.00M | 94751.00M | 41869.00M |
| Short term investments | 28069.00M | 36963.00M | 26254.00M | 34669.00M | 3005.00M |
| Net receivables | 50537.00M | 50879.00M | 43676.00M | 33617.00M | 28314.00M |
| Accounts payable | 32864.00M | 28978.00M | 20557.00M | 17295.00M | 14516.00M |
| Non currrent assets other | 4463.00M | 2035.00M | 2409.00M | 2099.00M | 2703.00M |
| Non current assets total | 197174.00M | 147107.00M | 109013.00M | 100294.00M | 73320.00M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Investments | 8205.00M | -13887.00M | 8698.00M | -29805.00M | -1595.00M |
| Change to liabilities | 129.00M | 6568.00M | 2238.00M | 1112.00M | 304.00M |
| Total cashflows from investing activities | -21933.00M | -23407.00M | 3592.00M | -49883.00M | -8783.00M |
| Net borrowings | -809.00M | -13.00M | 180.00M | -186.00M | -878.00M |
| Total cash from financing activities | -22837.00M | -16371.00M | -11615.00M | 43400.00M | -5008.00M |
| Change to operating activities | -2134.00M | -31091.00M | 3120.00M | 999.00M | -1056.00M |
| Net income | 49028.00M | 63845.00M | 37822.00M | 21635.00M | 19577.00M |
| Change in cash | 14066.00M | 15109.00M | 41196.00M | 20409.00M | 3806.00M |
| Begin period cash flow | 104253.00M | 89144.00M | 47948.00M | 27538.00M | 23732.00M |
| End period cash flow | 118319.00M | 104253.00M | 89144.00M | 47948.00M | 27538.00M |
| Total cash from operating activities | 57113.00M | 52108.00M | 46627.00M | 26789.00M | 17749.00M |
| Issuance of capital stock | 90.00M | 126.00M | 139.00M | 50183.00M | 47.00M |
| Depreciation | 7434.00M | 6274.00M | 5736.00M | 4493.00M | 1391.00M |
| Other cashflows from investing activities | -1593.00M | -3660.00M | -511.00M | -1824.00M | -579.00M |
| Dividends paid | 10860.00M | 8144.00M | 5768.00M | 4533.00M | 3353.00M |
| Change to account receivables | 3085.00M | -8836.00M | -9488.00M | -4216.00M | -2736.00M |
| Sale purchase of stock | - | - | - | - | -1.00M |
| Other cashflows from financing activities | -11258.00M | -8340.00M | -6166.00M | -2064.00M | -823.00M |
| Change to netincome | -25719.00M | -16994.00M | -13243.00M | -10209.00M | -11096.00M |
| Capital expenditures | 5911.00M | 1705.00M | 1230.00M | 1848.00M | 677.00M |
| Change in working capital | 1295.00M | -1698.00M | -6419.00M | -3055.00M | -3159.00M |
| Other non cash items | -2956.00M | -1629.00M | 1996.00M | 685.00M | 290.00M |
| Free cash flow | 49536.00M | 48891.00M | 44638.00M | 23949.00M | 16404.00M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MTHRY M3 Inc |
-0.65 11.40% |
5.05 | 31.84 | 26.25 | 0.05 | 4.60 | 0.04 | 0.12 |
| VEEV Veeva Systems Inc Class A |
5.51 1.82% |
308.72 | 43.49 | 29.59 | 12.48 | 5.79 | 10.39 | 33.41 |
| PMCUF Pro Medicus Limited |
- -% |
132.14 | 64.90 | 90.91 | 49.11 | 38.05 | 65.12 | 83.47 |
| TEM Tempus AI, Inc. Class A Common Stock |
-2.14 2.75% |
75.66 | - | - | 8.68 | 25.39 | 8.33 | - |
| BTSG BrightSpring Health Services, Inc. Common Stock |
- -% |
69.84 | 100.22 | 40.65 | 0.69 | 4.92 | 0.92 | 25.80 |
M3, Inc. provides medical-related services primarily to physicians and other healthcare professionals through Internet. The company operates through five reporting segments: Medical Platform, Evidence Solutions, Career Solutions, Site Solutions, and Overseas. It operates m3.com, a members-only web site for providing information to the healthcare professionals; MR-kun, where member doctors can independently and continuously receive information on the m3com platform; QOL-kun that provides life support information other than medical information to members; AskDoctors, where registered doctors answer questions about health and illness from the general public; MDLinx for medical professionals in the United States; and Doctors.net.uk, a website that provides developing services for pharmaceutical companies, as well as provides drug information database in France, Germany, and Spain. The company also provides career services for doctors and pharmacists, recruitment, and posting job advertisements through m3.com CAREER. In addition, it engages in the sales activities and marketing operations for pharmaceuticals and medical devices; development, sale, and support business of electronic medical records and medical equipment for medical institutions; survey service for medical professionals; sale and marketing support businesses for pharmaceutical companies, etc. through the Internet; provision of management support and consulting services to medical institutions, and home-visit nursing services; and provision of human resources services for healthcare professionals, as well as operates clinical trial facilities. The company was formerly known as So-netM3, Inc. and changed its name to M3, Inc. in January 2010. M3, Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan.
| Name | Title | Year Born |
|---|---|---|
| Mr. Itaru Tanimura | Pres and Representative Director | 1965 |
| Mr. Paul J. Rice | Chief Operating Officer of European Operations | NA |
| Dr. Timothy Richard Ringrose MRCP | Chief Exec. Officer of M3 EU | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.